Asymmetric dimethylarginine (ADMA) is a potent endogenous inhibitor of endothelial nitric oxide synthase (eNOS), which affects NO production and subsequently causes endothelial dysfunction [47]. Here, NOS3 is linked to endothelial dysfunction.